Differential effects of acute administration of clozapine or haloperidol on local cerebral glucose utilization in the rat

Brain Research

Volumn 768, Issue 1-2, 1997, Pages 273-278

  Colangelo, Vittorio ^a   Di Grezia, Renato ^a   Passarelli, Francesca ^b   Musicco, Massimo ^c   Pontieri, Francesco E ^b   Orzi, Francesco ^a,b  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CNR   (Italy)

Author keywords

Clozapine; Deoxyglucose; Extrapyramidal; Haloperidol; Limbic system; Nucleus accumbens

Indexed keywords

CLOZAPINE; HALOPERIDOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG RECEPTOR BINDING; ELECTROPHYSIOLOGY; GLUCOSE BRAIN LEVEL; GLUCOSE UTILIZATION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; BRAIN MAPPING; CLOZAPINE; GLUCOSE; HALOPERIDOL; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0030754314     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00650-1     Document Type: Article

References (32)

1. Bolden Watson C., Watson M.A., Murray K.D., Isackson P.J., Richelson E. Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia nigra. J. Neurochem. 61:1993;1141-1143.
2. Chiodo L.A., Bunney B.S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J. Neurosci. 3:1983;1607-1619.
3. Chiodo L.A., Bunney B.S. Possible mechanism by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J. Neurosci. 5:1985;2539-2544.
4. Daly D.A., Moghaddam B. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci. Lett. 152:1993;61-64.
5. Deutch A.Y., Lee M.C., Iadarola M. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol. Cell. Neurosci. 3:1992;332-341.
6. Farde' L., Wiesel F.A., Nordstrom A.L., Sedvall G. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology. 99:1989;S28-S31.
7. 1C receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus after chronic treatment with clozapine. Eur. J. Pharmacol. 255:1994;91-97.
8. Kurachi M., Yasui S., Shibata R., Murata M., Hagino H., Kurachi T., Tanii Y., Kurata K. Comparative study of dopamine metabolism with local cerebral glucose utilization in rat brain following the administration of haloperidol decanoate. Biol. Psychiatry. 36:1994;110-117.
9. Lidsky T.I., Yablonsky-Alter E., Zuck L., Banerjee S.P. Anti-glutamatergic effects of clozapine. Neurosci. Lett. 163:1993;155-158.
10. MacGibbon G.A., Lawlor P.A., Bravo R., Dragunow M. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Mol. Brain Res. 23:1994;21-32.
11. Marcus M.M., Nomikos G.G., Svensson T.H. Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur. Neuropsychopharmacol. 6:1996;29-38.
12. McCulloch J., Savaki H.E., Sokoloff L. Distribution of effects of haloperidol on energy metabolism in the rat brain. Brain Res. 243:1982;81-90.
13. i values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
14. Merchant K.M., Dobner P.R., Dorsa D.M. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J. Neurosci. 12:1992;652-663.
15. Mercugliano M., Saller C.F., Salama A.I., U'Prichard D.C., Chessele M.F. Clozapine and haloperidol have differential effects on glutamic acid decarboxylase mRNA in the pallidal nuclei of the rat. Neuropsychopharmacology. 6:1992;179-187.
16. Morelli M., Pontieri F.E., Linfante I., Orzi F., Di Chiara G. Local cerebral glucose utilization after D1 receptor stimulation in 6-OHDA lesioned rats: effect of sensitization (priming) with a dopaminergic agonist. Synapse. 13:1993;264-269.
17. Murray A.M., Hyde T.M., Knable M.B., Herman M.M., Bigelow L.B., Carter J.M., Weinberger D.R., Kleinman J.E. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci. 15:1995;2186-2191.
18. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., Hyman S.E. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc. Natl. Acad. Sci. USA. 89:1992;4270-4274.
19. Palombo E., Porrino L.J., Bankiewicz K.S., Crane A.M., Sokoloff L., Kopin I.J. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by unilateral intracarotid infusion of the neurotoxin MPTP. J. Neurosci. 10:1990;860-869.
20. Pizzolato G., Soncrant T.T., Larson D.M., Rapoport S.I. Reduced metabolic response of the rat brain to haloperidol after chronic treatment. Brain Res. 337:1985;1-9.
21. Rebec G.V., Bashore T.R., Zimmerman K.S. Neostriatal and mesolimbic neurones: dose dependent effects of clozapine. Neuropharmacology. 19:1980;281-288.
22. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience. 46:1992;315-328.
23. Seeman P., Guan H.C., Van Tol H.H.M. Dopamine D4 receptors elevated in schizophrenia. Nature. 365:1993;441-445.
24. 14C]-deoxyglucose method for measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 28:1977;897-916.
25. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 347:1990;146-151.
26. Squires R.F., Saederup E. Mono N-aryl ethylenediamine and piperazine derivatives are GABAA receptor blockers: implications for psychiatry. Neurochem. Res. 18:1993;787-793.
27. Stockmeier C.A., DiCarlo J.J., Zhang Y., Thompson P., Meltzer H.Y. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J. Pharmacol. Exp. Ther. 266:1993;1374-1384.
28. C.A. Tamminga, J. Gerlach, New neuroleptics and experimental antipsychotics in schizophrenia, in: H.Y. Meltzer (Ed.), Psychopharmacology: the Third Generation of Progress, Raven Press, New York, 1987, pp. 1129-1140.
29. Van Tol H.H.M., Bunzow J.R., Hong-Chang G., Sunahara R.K., Seeman P., Niznik H.B., Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 350:1991;614-619.
30. White F.J., Wang R.Y. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurones. Science. 221:1983;1054-1057.
31. Wooten G.F., Collins R.C. Metabolic effects of unilateral lesion of the substantia nigra. J. Neurosci. 1:1981;285-291.
32. Yamamoto B.K., Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14:1994;4159-4166.